Adding Insult to Injury: Does COVID-19 Promote Acute Respiratory Distress Syndrome by Inhibiting Surfactant?
作者信息
Richmond Bradley W, Dela Cruz Charles S
机构信息
Department of Veterans Affairs Nashville, Tennessee.
Division of Allergy, Pulmonary, and Critical Care Medicine Vanderbilt University Medical Center Nashville, Tennessee.
出版信息
Am J Respir Crit Care Med. 2023 Jan 1;207(1):5-6. doi: 10.1164/rccm.202208-1549ED.
Abstract
摘要
相似文献
1
Adding Insult to Injury: Does COVID-19 Promote Acute Respiratory Distress Syndrome by Inhibiting Surfactant?雪上加霜：新冠病毒是否通过抑制表面活性剂来引发急性呼吸窘迫综合征？
Am J Respir Crit Care Med. 2023 Jan 1;207(1):5-6. doi: 10.1164/rccm.202208-1549ED.
2
Surfactant therapy for acute lung injury and acute respiratory distress syndrome.表面活性物质治疗急性肺损伤和急性呼吸窘迫综合征。
Crit Care Clin. 2011 Jul;27(3):525-59. doi: 10.1016/j.ccc.2011.04.005.
3
Surfactant replacement therapy as promising treatment for COVID-19: an updated narrative review.表面活性物质替代疗法作为 COVID-19 的有前途的治疗方法：更新的叙述性综述。
Biosci Rep. 2023 Aug 31;43(8). doi: 10.1042/BSR20230504.
4
Natural Versus Synthetic Surfactant Therapy in Respiratory Distress Syndrome of Prematurity: Correspondence.天然与合成表面活性剂治疗早产儿呼吸窘迫综合征：通信
Indian J Pediatr. 2022 Nov;89(11):1159. doi: 10.1007/s12098-022-04336-4. Epub 2022 Jul 20.
5
[Surfactant therapy of respiratory distress syndrome].[呼吸窘迫综合征的表面活性剂治疗]
Ugeskr Laeger. 2021 Nov 1;183(44).
6
Lung Mechanics in COVID-19 Resemble Respiratory Distress Syndrome, Not Acute Respiratory Distress Syndrome: Could Surfactant Be a Treatment?新型冠状病毒肺炎中的肺力学类似呼吸窘迫综合征，而非急性呼吸窘迫综合征：表面活性剂能否成为一种治疗方法？
Am J Respir Crit Care Med. 2020 Aug 15;202(4):624-626. doi: 10.1164/rccm.202004-1471LE.
7
Exogenous pulmonary surfactant in COVID-19 ARDS. The similarities to neonatal RDS suggest a new scenario for an 'old' strategy.COVID-19 所致急性呼吸窘迫综合征中的外源性肺表面活性剂。其与新生儿呼吸窘迫综合征的相似之处提示了一种“老”策略的新方案。
BMJ Open Respir Res. 2021 Sep;8(1). doi: 10.1136/bmjresp-2020-000867.
8
Less invasive surfactant administration: Will it change the outcome of preterm infants with respiratory distress syndrome?微创表面活性剂给药：它会改变患有呼吸窘迫综合征的早产儿的结局吗？
J Chin Med Assoc. 2020 Aug;83(8):699-700. doi: 10.1097/JCMA.0000000000000322.
9
Bovine surfactant in the treatment of pneumonia-induced-neonatal acute respiratory distress syndrome (NARDS) in neonates beyond 34 weeks of gestation: a multicentre, randomized, assessor-blinded, placebo-controlled trial.牛肺表面活性物质治疗孕34周以上新生儿肺炎所致新生儿急性呼吸窘迫综合征（NARDS）：一项多中心、随机、评估者盲法、安慰剂对照试验
Eur J Pediatr. 2021 Apr;180(4):1107-1115. doi: 10.1007/s00431-020-03821-2. Epub 2020 Oct 21.
10
Less invasive surfactant administration by umbilical catheter is safe and effective for treating respiratory distress syndrome in preterm infants.通过脐静脉导管进行的微创表面活性剂给药对治疗早产儿呼吸窘迫综合征是安全有效的。
Acta Paediatr. 2023 Apr;112(4):706-707. doi: 10.1111/apa.16650. Epub 2023 Jan 2.
引用本文的文献
1
The anti-inflammatory and antiviral properties of anionic pulmonary surfactant phospholipids.阴离子肺表面活性剂磷脂的抗炎和抗病毒特性。
Immunol Rev. 2023 Aug;317(1):166-186. doi: 10.1111/imr.13207. Epub 2023 May 5.
本文引用的文献
1
Pulmonary Surfactant Proteins Are Inhibited by Immunoglobulin A Autoantibodies in Severe COVID-19.严重 COVID-19 患者的免疫球蛋白 A 自身抗体可抑制肺表面活性剂蛋白。
Am J Respir Crit Care Med. 2023 Jan 1;207(1):38-49. doi: 10.1164/rccm.202201-0011OC.
2
New-onset IgG autoantibodies in hospitalized patients with COVID-19.新型冠状病毒肺炎住院患者新出现的IgG自身抗体
Nat Commun. 2021 Sep 14;12(1):5417. doi: 10.1038/s41467-021-25509-3.
3
IgG and IgA autoantibodies against L1 ORF1p expressed in granulocytes correlate with granulocyte consumption and disease activity in pediatric systemic lupus erythematosus.针对粒细胞中表达的 L1 ORF1p 的 IgG 和 IgA 自身抗体与儿童系统性红斑狼疮中的粒细胞消耗和疾病活动相关。
Arthritis Res Ther. 2021 May 29;23(1):153. doi: 10.1186/s13075-021-02538-3.
4
Diverse functional autoantibodies in patients with COVID-19.COVID-19 患者中的多种功能性自身抗体。
Nature. 2021 Jul;595(7866):283-288. doi: 10.1038/s41586-021-03631-y. Epub 2021 May 19.
5
Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract.流感病毒和 SARS-CoV-2：呼吸道中的发病机制和宿主反应。
Nat Rev Microbiol. 2021 Jul;19(7):425-441. doi: 10.1038/s41579-021-00542-7. Epub 2021 Apr 6.
6
Autoantibodies against type I IFNs in patients with life-threatening COVID-19.COVID-19 危重症患者体内针对 I 型干扰素的自身抗体。
Science. 2020 Oct 23;370(6515). doi: 10.1126/science.abd4585. Epub 2020 Sep 24.
7
Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey.新型冠状病毒肺炎住院患者中急性呼吸窘迫综合征的发病率及预后：一项全球文献综述
Crit Care. 2020 Aug 21;24(1):516. doi: 10.1186/s13054-020-03240-7.
8
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19.新型冠状病毒肺炎的肺血管内皮细胞炎症、血栓形成和血管生成。
N Engl J Med. 2020 Jul 9;383(2):120-128. doi: 10.1056/NEJMoa2015432. Epub 2020 May 21.
9
On the molecular determinants of the SARS-CoV-2 attack.关于严重急性呼吸综合征冠状病毒2（SARS-CoV-2）侵袭的分子决定因素
Clin Immunol. 2020 Jun;215:108426. doi: 10.1016/j.clim.2020.108426. Epub 2020 Apr 18.
10
Surfactant replacement therapy for preterm and term neonates with respiratory distress.表面活性物质替代疗法治疗有呼吸窘迫的早产儿和足月儿。
Pediatrics. 2014 Jan;133(1):156-63. doi: 10.1542/peds.2013-3443. Epub 2013 Dec 30.
Zotero 插件